Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Hereditary Hemorrhagic Telangiectasia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    14 result(s) found for: Hereditary Hemorrhagic Telangiectasia. Displaying page 1 of 1.
    EudraCT Number: 2017-003272-31 Sponsor Protocol Number: NL.EPITRAC.0107.17 Start Date*: 2018-05-18
    Sponsor Name:St. Antonius Ziekenhuis
    Full Title: Efficacy and safety of oral itraconazole in the reduction of epistaxis severity in hereditary hemorrhagic telangiectasia
    Medical condition: Severe epistaxis in patients with Hereditary Hemorrhagic Telangiectasia also known as Rendu-Osler-Weber disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10031132 Osler-Weber-Rendu disease LLT
    20.0 100000004850 10038554 Rendu-Osler-Weber syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-004096-36 Sponsor Protocol Number: THALI-HHT Start Date*: 2011-10-11
    Sponsor Name:OSPEDALE POLICLINICO S. MATTEO
    Full Title: Efficacy of thalidomide in the treatment of severe recurrent epistaxis in hereditary hemorrhagic telangiectasia (HHT)
    Medical condition: Severe recurrent epistaxis in hereditary hemorrhagic telangiectasia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10038554 Rendu-Osler-Weber syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-003982-24 Sponsor Protocol Number: HHT-HOPE-2016 Start Date*: 2017-03-16
    Sponsor Name:Asociación HHT España
    Full Title: A phase IV-II, single-center, open, single arm treatment, low level of intervention, to assess the efficacy clinical trial and safety of intranasal administration of ethamsylate in the treatment of...
    Medical condition: Hereditary hemorrhagic telangiectasia
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004850 10020023 HHT LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-000385-55 Sponsor Protocol Number: 69HCL15_0063 Start Date*: 2015-05-12
    Sponsor Name:Hospices Civils de Lyon
    Full Title: TEMPO : Efficacité du TIMOLOL en administration nasale pour le traitement des épistaxis dans la maladie de Rendu-Osler. Essai randomisé en double insu contre placebo
    Medical condition: Rendu-Osler disease
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004850 10031132 Osler-Weber-Rendu disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-004204-19 Sponsor Protocol Number: 2013-827 Start Date*: 2014-02-26
    Sponsor Name:Hospices Civils de Lyon
    Full Title: Efficacité du bevacizumab en spray nasal pour le traitement des épistaxis dans la maladie de Rendu-Osler
    Medical condition: Rendu-Osler disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004850 10031132 Osler-Weber-Rendu disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-006755-44 Sponsor Protocol Number: 2008-510 Start Date*: 2009-01-15
    Sponsor Name:HOSPICES CIVILS DE LYON
    Full Title: METAFORE : Maladie de Rendu-Osler : Etude de l’Efficacité et de la tolérance du Bevacizumab utilisé pour le traitement des formes hépatiques sévères. Etude de phase II
    Medical condition: Maladie de Rendu-Osler
    Disease: Version SOC Term Classification Code Term Level
    9.1 10031132 Osler-Weber-Rendu disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003585-40 Sponsor Protocol Number: NL.TACRO.10.7.19 Start Date*: 2019-12-17
    Sponsor Name:St. Antonius Hospital
    Full Title: An uncontrolled, open label pilot-study assessing the efficacy in reducing bleeding severity, and the safety of oral tacrolimus in patients with hereditary hemorrhagic telangiectasia
    Medical condition: Gastrointestinal bleeding and epistaxis caused by hereditary hemorrhagic telangiectasia. Hereditary Hemorrhagic Telangiectasia (HHT) is an autosomal dominant inherited disease characterized by muco...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10038554 Rendu-Osler-Weber syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-004179-11 Sponsor Protocol Number: 2018-4898 Start Date*: 2019-06-03
    Sponsor Name:Radboudumc
    Full Title: Effectiveness of Somatostatin Analogues in Patients with hereditary hemorrhagic telangiectasia and symptomatic gastrointestinal bleeding, the SAIPAN-trial: a multicenter, randomized, open-label, pa...
    Medical condition: Hereditary hemorrhagic telangiectasia (HHT)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) DE (Ongoing) FR (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-001031-39 Sponsor Protocol Number: 69HCL17_0018 Start Date*: 2017-05-19
    Sponsor Name:Hospices Civils de Lyon
    Full Title: BABH Study: Efficacy and safety of bevacizumab on severe bleedings associated with Hemorrhagic Hereditary Telangiectasia (HHT). A National, randomized multicenter phase III study.
    Medical condition: Hemorrhagic Hereditary Telangiectasia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10031132 Osler-Weber-Rendu disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004730-18 Sponsor Protocol Number: OSLER_TIMOLOL Start Date*: 2019-12-11
    Sponsor Name:University Hospital Regensburg
    Full Title: The influence of Timolol Nasal Spray on Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)
    Medical condition: 2) hereditary hemorrhagic telangiectasia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10031132 Osler-Weber-Rendu disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002593-31 Sponsor Protocol Number: 69HCL19_0003 Start Date*: 2019-11-05
    Sponsor Name:Hospices Civils de Lyon
    Full Title: Efficacy of Nintedanib per os as a treatment for epistaxis in HHT disease A national, randomized, multicenter phase II study EPICURE
    Medical condition: Hereditary Hemorrhagic Telangiectasia
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004850 10019887 Hereditary hemorrhagic telangiectasia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2010-020545-26 Sponsor Protocol Number: HHT-BA0801 Start Date*: 2008-12-09
    Sponsor Name:AZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALE
    Full Title: BEVACIZUMAB, AN ANTI-ANGIOGENIC MONOCLONAL ANTIBODY EFFECTIVE FOR PREVENTION OF HEMORRHAGING IN PATIENTS WITH HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT): POSSIBLE REGRESSION OF VISCERAL ARTERIOVEN...
    Medical condition: HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10005329 SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-001340-19 Sponsor Protocol Number: NLROW.1012.15 Start Date*: 2016-07-21
    Sponsor Name:Radboud University Medical Center
    Full Title: An uncontrolled, pilot-study assessing the efficacy of octreotide LAR to decrease transfusion requirements and endoscopy frequency in patients with Rendu-Osler-Weber and gastrointestinal bleeding
    Medical condition: Patients with Rendu-Osler-Weber disease (which is also called: Hereditary hemorrhagic telangiectasia)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-018049-19 Sponsor Protocol Number: Start Date*: 2010-12-13
    Sponsor Name:Medizinische Universität Wien,Univ.Klinik f.Hals-, Nasen- und Ohrenkrankheiten
    Full Title: A randomized double blind placebo controlled trial of intranasal submucosal bevacizumab in hereditary hemorrhagic telangiectasia
    Medical condition: epistaxis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 18 08:49:27 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA